Key Highlights

  • Revenue of USD 342.29 million compares with an estimate of USD 332.58 million and USD 278.63 million a year earlier.
  • EPS was USD 0.31 against an estimate of USD 0.20 and USD 0.42 in the third quarter of 2025.
  • DAYBUE net sales were USD 140 million against USD 101 million, and NUPLAZID USD 202 million against USD 178 million.
  • 2026 DAYBUE net sales guidance was raised to a range of USD 505 million to USD 520 million.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) updated its 2026 guidance alongside third quarter results, raising DAYBUE net sales to a range of USD 505 million to USD 520 million, up from USD 480 million to USD 510 million. Third quarter Revenue was USD 342.29 million, against an estimate of USD 332.58 million and USD 278.63 million a year earlier. EPS was USD 0.31, against an estimate of USD 0.20.

Revised 2026 Guidance by Line

Total revenue guidance was revised to USD 1.265 billion to USD 1.295 billion, compared with a previous range of USD 1.24 billion to USD 1.30 billion. NUPLAZID net product sales were narrowed to USD 760 million to USD 775 million from USD 760 million to USD 790 million.

On the cost side, Research and Development expense is guided to USD 325 million to USD 340 million, down from USD 355 million to USD 380 million. Selling, general and administrative expense is guided to USD 665 million to USD 685 million, against a prior range of USD 660 million to USD 700 million.

The Quarter in Detail

Revenue consists entirely of net product sales. The company stated that total revenue rose 23% from USD 279 million a year earlier on a GAAP basis, and 22% against non-GAAP adjusted revenue of USD 281 million. Income from operations was USD 71.72 million against USD 35.76 million.

Research and development expense was USD 76.28 million against USD 87.83 million, while selling, general and administrative expense was USD 159.20 million against USD 133.40 million. Income tax expense was USD 26.92 million, compared with a benefit of USD 27.18 million a year earlier. Net Income was USD 53.52 million, or USD 0.31 per diluted share, against USD 71.78 million, or USD 0.42.

For the nine months, revenue was USD 918.31 million against USD 787.52 million, and net income was USD 88.66 million against USD 117.43 million.

DAYBUE, NUPLAZID and the Pipeline

DAYBUE net sales rose 39% to USD 140 million from USD 101 million, which the company tied to uptake of DAYBUE STIX in the United States. NUPLAZID net sales were USD 202 million, up 14% from USD 178 million on a GAAP basis and up 12% against non-GAAP adjusted sales of USD 180 million. Chief executive Catherine Owen Adams said the commercial franchises provide the financial foundation for clinical programs.

In Europe, the European Commission approved DAYBU for Rett syndrome in August 2026, and the product launched in Germany in early October. A new U.S. Patent allowance covering weight-banded dosing extends protection for DAYBUE and DAYBUE STIX through March 2041. In Japan the company completed a Phase 3 trofinetide study, pursues a distribution partner and plans a regulatory filing in 2027, with a potential launch in 2028 subject to approval.

In the pipeline, topline results from the Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis supported continued Phase 3 development. The FDA granted Fast Track Designation to remlifanserin for Lewy body dementia psychosis.

Guidance Versus Reported Results

Third quarter revenue of USD 342.29 million sits alongside nine-month revenue of USD 918.31 million, full-year revenue guidance of USD 1.265 billion to USD 1.295 billion and cash and Investment securities of USD 976.4 million.

Cash and investment securities were USD 819.7 million at December 31, 2025. Additional RADIANT data are scheduled for presentation at the Clinical Trials on Alzheimer's Disease conference in Boston on November 17, 2026. Management named two Phase 2 readouts in 2027, with ACP-211 in major depressive disorder in the second half and remlifanserin in Lewy body dementia psychosis in the fourth quarter.